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Abstract: Enhanced control of species of Cryptococcus, non-fermentative yeast pathogens, 
was achieved by chemosensitization through co-application of certain compounds with a 
conventional antimicrobial drug. The species of Cryptococcus tested showed higher 
sensitivity to mitochondrial respiratory chain (MRC) inhibition compared to species of 
Candida. This higher sensitivity results from the inability of Cryptococcus to generate cellular 
energy through fermentation. To heighten disruption of cellular MRC, octyl gallate (OG) 
or 2,3-dihydroxybenzaldehyde (2,3-DHBA), phenolic compounds inhibiting mitochondrial 
functions, were selected as chemosensitizers to pyraclostrobin (PCS; an inhibitor of 
complex III of MRC). The cryptococci were more susceptible to the chemosensitization 
(i.e., PCS + OG or 2,3-DHBA) than the Candida with all Cryptococcus strains tested being 
sensitive to this chemosensitization. Alternatively, only few of the Candida strains showed 
sensitivity. OG possessed higher chemosensitizing potency than 2,3-DHBA, where the 
concentration of OG required with the drug to achieve chemosensitizing synergism was 
much lower than that required of 2,3-DHBA. Bioassays with gene deletion mutants of the 
model yeast Saccharomyces cerevisiae showed that OG or 2,3-DHBA affect different 
cellular targets. These assays revealed mitochondrial superoxide dismutase or glutathione 
homeostasis plays a relatively greater role in fungal tolerance to 2,3-DHBA or OG, 
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respectively. These findings show that application of chemosensitizing compounds  
that augment MRC debilitation is a promising strategy to antifungal control against  
yeast pathogens. 
Keywords: chemosensitization; Cryptococcus; Candida; Saccharomyces; octyl gallate;  
2,3-dihydroxybenzaldehyde; mitochondrial respiration inhibitors 
 
1. Introduction 
Mycotic infectious diseases, such as candidiasis or cryptococcosis caused by various species of 
Candida or Cryptococcus, respectively, are continuously expanding as serious global health issues. 
This expansion is mainly associated with immunocompromised disorders (e.g., AIDS, chemotherapy, 
radiotherapy, etc.) [1] and concomitant development of resistance to antifungal drugs [2]. 
Consequently, there is persistent need to enhance the effectiveness of conventional antimycotic drugs 
or discover and develop new ones [3]. 
Mitochondrial functions of fungi have been examined as potential targets for antifungal therapy ([4] 
for review). For example, certain mitochondrial mutants exhibited increased susceptibility to polyene 
or azole drugs, possibly resulting from changes in sterol levels of membranes ([4] and references 
therein). In particular, the mitochondrial respiratory chain (MRC; See Figure 1 for the structure of 
MRC) is a target of the MRC-inhibitory drug atovaquone (ATQ; hydroxy-1,4-naphthoquinone) for 
control of the infections of fungi, such as Pneumocystis jirovecii (pneumonia) [5]. Such  
MRC-inhibitory drugs disrupt production of cellular energy (ATP) in fungal cells. Of note, ATQ is 
also used to treat malarial parasites, such as Plasmodium, where ATQ not only inhibits the MRC, but 
also disrupts the inner mitochondrial membrane potential (ΔΨm) [6]. 
MRC inhibitors can also trigger oxidative stress resulting from leakage of electrons from the MRC, 
resulting in oxidative damage to cellular components, such as cell membranes/lipid bilayers. This 
demonstrates that the fungal antioxidant system (superoxide dismutases, glutathione reductase, stress 
signaling pathway, etc.) plays a crucial role in maintaining cellular integrity from toxic reactive 
oxygen species [7,8]. To date, while the MRC has been targeted for control of agro-fungal pathogens, 
it has been a relatively unexploited drug target against clinical fungal pathogens. 
Antifungal MRC targeting could possibly be enhanced by compounds affecting cellular redox 
homeostasis. Natural phenolic compounds or their structural derivatives, which are redox-active, can 
serve as potent redox cyclers against fungal pathogens, resulting in inhibition of microbial growth ([9] 
and references therein). This inhibition results from destabilization of cellular redox homeostasis, 
antioxidant systems or the function of redox-sensitive components [10,11]. Meanwhile, certain phenolic 
compounds/derivatives can also inhibit various functions of mitochondrial components (See Table 1). For 
example, gallate derivatives, such as propyl- or octyl gallate (PG or OG, respectively), inhibit the 
activity of cellular alternative oxidase (AOX). AOX functions in fungi to overcome the toxicity triggered 
by MRC inhibitors, rendering the completion of electron transfer via MRC ([12,13]; See Figure 1). OG 
further disrupts and/or disorganizes the lipid bilayer-protein interface in fungal cells [14]. Likewise, 
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acetylsalicylic acid (AcSA) or 2,3-dihydroxybenzaldehyde (2,3-DHBA) also inhibits the functions of 
mitochondria or mitochondrial superoxide dismutase (Mn-SOD), respectively, in fungi [15,16]. 
Figure 1. Schematic representation of MRC (Adapted from [17] and [18]). CoQ, 
Coenzyme Q; CytC, Cytochrome C; e−, Electrons; Dashed line (black), Electron flow w/o 
MRC inhibition; Dashed line (red), Electron flow through AOX when MRC is inhibited.  
I to V, complexes I to V of MRC. 
 
Chemosensitization is a strategy where co-application of certain types of compounds along with a 
conventional antimicrobial drug increases the effectiveness of the drug [19–22]. Examples include:  
(1) 4-methoxy-2,3,6-trimethylbenzensulfonyl-substituted D-octapeptide, which sensitizes pathogenic 
Candida strains to fluconazole (FLC), resulting in countering FLC resistance of clinical isolates [22], 
(2) 7-chlorotetrazolo[5,1-c]benzo[1,2,4]triazine (CTBT), which increases the susceptibility of Candida 
and Saccharomyces strains to cycloheximide, 5-fluorocytosine and azole drugs [23], (3) squalamine  
(a modifier of membrane integrity by increasing permeability of drugs), which enhances the 
susceptibility of various antibiotic-resistant and susceptible strains of Gram-negative bacteria to  
drugs [21], and (4) antimycin A (AntA) and benzhydroxamic acid (BHAM), which makes Rhizopus 
oryzae hypersensitive to triazoles, i.e., posaconazole (PCZ) and itraconazole (ICZ), via apoptosis [24]. 
Collectively, these studies showed that antimicrobial drug therapy that includes chemosensitization 
could lead to lowering dosage levels of conventional drugs needed for control of pathogens, in both 
drug-resistant and susceptible strains. 
Various species of Cryptococcus and Candida are human and animal pathogens. For example, 
cryptococcal meningitis is reported to be the leading cause of death among those infected with HIV [25]. 
However, one of the key differences between the yeasts in these two genera is that species of 
Cryptococcus are non-fermentative, while the Candida species are fermentative [16]. 
  
Molecules 2013, 18 8876 
 
 
Table 1. Mitochondrial targets and structures of compounds tested in this study. 
Compounds Target References 
2,3-DHBA Mn-SOD (Saccharomyces cerevisiae  
Mn-SOD gene deletion mutant is 




General mitochondrial function 
(Aspergillus fumigatus sakAΔ [oxidative 
stress-responsive mitogen-activated protein 
kinase gene deletion mutant] was also 








Based on this difference, we reasoned the following: (1) When cellular MRC is disrupted by  
MRC-inhibitory drug(s), the Cryptococcus would show higher sensitivity than the Candida, (2) This 
higher sensitivity is due to the fact that the Candida can generate cellular energy also through 
fermentation (other than MRC), while the Cryptococcus, being non-fermentative, lack this ability,  
and (3) Thus, MRC could serve as an effective antifungal target especially for control of  
Cryptococcus pathogens. 
In this study, we investigated if selected phenolic compounds/derivatives (See Table 1) could 
enhance the antifungal potency of pyraclostrobin (PCS), the most potent complex III inhibitor of MRC 
in our test, against Cryptococcus. Our hypothesis was that co-application of phenolic 
compounds/derivatives (as chemosensitizers) and PCS will negatively affect the common cellular 
target, i.e., functions of mitochondria, resulting in increased sensitivity of fungi. We also evaluated the 
potential of these chemosensitizing compounds to serve as active pharmaceutical “leads” against 
Cryptococcus yeasts, and compared the effectiveness of chemosensitization between Cryptococcus and 
Candida (See Table 2 for strains tested). Our results showed that the Cryptococcus were more 
susceptible to OG- or 2,3-DHBA-mediated chemosensitization to PCS than the Candida, where the 
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Table 2. Yeast strains used in this study. 
Yeast strains Strain characteristics Source/Reference 
Cryptococcus   
C. neoformans 90112 Clinical reference strain ATCC a 
C. neoformans 208821 Clinical isolate ATCC 
C. neoformans MYA-4564 Clinical reference strain ATCC 
C. neoformans MYA-4565 Clinical reference strain ATCC 
C. neoformans MYA-4566 Clinical reference strain ATCC 
C. neoformans MYA-4567 Clinical reference strain ATCC 
C. neoformans CN24 Clinical isolate IHMT b 
C. gatti MYA-4560 Clinical reference strain ATCC 
C. gatti MYA-4561 Clinical reference strain ATCC 
Candida   
C. albicans 90028 Clinical reference strain ATCC 
C. albicans CAN242 Clinical isolate IHMT 
C. albicans CAN276 Clinical isolate IHMT 
C. glabrata 90030 Clinical reference strain ATCC 
C. glabrata 2001 Clinical reference strain ATCC 
C. glabrata CAN252 Clinical isolate IHMT 
C. krusei 6258 Clinical reference strain ATCC 
C. krusei CAN82 Clinical isolate IHMT 
C. krusei CAN75  Clinical isolate IHMT 
Saccharomyces   
S. cerevisiae BY4741 Model yeast, Parental strain 
(Mat a his3∆1 leu2∆0 met15∆0 ura3∆0) 
SGD c 
S. cerevisiae sod2∆ Mitochondrial superoxide dismutase  
(Mn-SOD) mutant derived from BY4741 
SGD 
S. cerevisiae yap1∆ Transcription factor YAP1 mutant derived 
from BY4741 
SGD 
S. cerevisiae trr1∆ Cytosolic thioredoxin reductase mutant 
derived from BY4741 
SGD 
S. cerevisiae trr2∆ 
 
S. cerevisiae tsa1∆ 
Mitochondrial thioredoxin reductase 
mutant derived from BY4741 





a.ATCC, American Type Culture Collection, Manassas, VA, USA; b.IHMT, Instituto de Higiene e Medicina 
Tropical/CREM, Universidade Nova de Lisboa, Portugal; c.SGD, Saccharomyces Genome Database [30]. 
2. Results and Discussion 
We initially tested the effect of chemosensitization by co-applying commercial 
antifungal/antimalarial drugs “ATQ + proguanil” on the growth of fermenting and non-fermenting 
yeast pathogens. For this test, we chose representative yeast pathogens, i.e., C. albicans 90028 as a 
fermentor, and C. neoformans 90112 and C. gatti 4560 as non-fermentors. In protozoan parasites,  
co-application of proguanil (a mitochondria-modulating chemosensitizer) increased anti-parasitic 
activity of ATQ [31]. Noteworthy is that proguanil-mediated chemosensitization was specific for ATQ. 
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Proguanil did not increase the potency of other types of MRC inhibitors (e.g., myxothiazole, AntA) [31]. 
Thus, these results with malarial parasites (Plasmodium) indicated “drug-chemosensitizer specificity” 
existed during the chemosensitization process. 
We used the checkerboard microdilution bioassay protocol outlined by the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) [32], with various concentrations of ATQ (0.25, 0.5, 
1, 2, 4, 8, 16 μg/mL) and proguanil (0.25, 0.5, 1, 2, 4, 8, 16 μg/mL). Our results showed that:  
(1) Independent application of ATQ or proguanil, alone, did not exhibit discernable growth inhibition 
in any of the test yeast strains, even at the highest concentration (i.e., 16 μg/mL), and also (2)  
Co-application of ATQ with proguanil did not enhance the antifungal activity of either compounds, 
indicating no chemosensitization occurred by “ATQ + proguanil” co-treatment in these strains (Data 
not shown). 
In the model yeast Saccharomyces cerevisiae, nine cellular transporters required for sequestering 
toxic drugs/compounds out of the cell need to be knocked out to exhibit ATQ sensitivity [33]. This 
indicates active drug-detoxification systems do operate in S. cerevisiae. We surmised that pathogenic 
yeasts, i.e., Cryptococcus or Candida, might also operate similar type(s) of detoxification system(s), 
enabling these pathogens to escape from ATQ/proguanil-triggered toxicity. Therefore, we performed 
chemosensitization tests using other types of MRC inhibitors with co-application of phenolic 
compounds (i.e., OG, PG, 2,3-DHBA, AcSA; See Table 1) as chemosensitizers. 
2.1. PCS Is the Most Potent MRC Inhibitor in Cryptococcus 
First, we identified the potency of MRC inhibitors tested against yeast pathogens. Antifungal 
efficacy was compared among 12 different MRC inhibitors disrupting one of the five different 
components of MRC, i.e., complexes I to IV or AOX (See Table 3, Figure 1). The level of differential 
sensitivity between fermenting (Candida) and non-fermenting (Cryptococcus) yeasts to the MRC 
inhibitors was determined by an agar plate-based yeast dilution bioassay (See Experimental section). 
We initially examined (1) three fermentors: C. albicans 90028, C. glabrata 90030, C. krusei 6258 and 
(2) two non-fermentors: C. neoformans 90112, C. gatti MYA-4560. 
MRC inhibitors targeting complex I, III or IV reduced the growth of the Cryptococcus, with 
differing levels of fungal sensitivity (Table 3, Figure 2a). For example, when C. neoformans 90112 
was treated with complex III inhibitors, growth was inhibited by 100 to 1000 times more compared to 
controls (i.e., log10 dilution score of “no treatment” controls was “6” [i.e., yeast cells appeared at the 
highest dilution level of 106] vs. log10 score of “treatments” was “3–4” [i.e., cells did not appear at 
dilution levels greater than103–104]), depending on types of complex III inhibitors applied. Also, 
rotenone (a complex I inhibitor) and Na-azide (a complex IV inhibitor) inhibited the growth of  
C. neoformans 90112 at cell dilution levels above 103 times. 
Growth of C. gatti 4560 was also decreased by four different MRC inhibitors (Table 3). However, 
unlike the results of C. neoformans 90112, AntA and AZS did not inhibit the growth of C. gatti 4560 
(Table 3). Moreover, besides carboxin, which inhibited C. neoformans 90112, both complex II and 
AOX inhibitors did not discernably inhibit the growth of C. neoformans 90112 or C. gatti 4560  
(See also Figure 2a). 
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Based on these initial bioassays, rotenone, Kre-Me, PCS and Na-azide (exhibiting antifungal 
activity against both C. neoformans 90112 and C. gatti 4560) were selected for further evaluation for 
antifungal potency against additional test strains (i.e., seven additional Cryptococcus and six additional 
Candida strains) (See Figure 2b). A similar trend of growth inhibition was found in these additional 
Cryptococcus strains with PCS and rotenone, while Kre-Me and Na-azide showed almost no effect. 
The growth of the additional Candida strains was not noticeably affected by any of these same 
treatments. In summary: (1) PCS possessed the highest antifungal activity (Average log10 dilution 
score = 3.4 ± 0.9, this lowest average log10 score was based upon the results using nine Cryptococcus 
strains shown in Figure 2a,b), followed by rotenone (average log10 score = 4.6 ± 1.2); (2) as expected, 
the growth of the Candida (fermenting yeasts) was not affected by any of the MRC inhibitors tested 
(Table 3; Figure 2a,b), and (3) thus, we chose PCS as the most potent MRC-inhibitory drug against 
Cryptococcus in our chemosensitization study. 
Table 3. Summary of levels of growth inhibition of representative yeast pathogens by 

















 None 6 6 6 6 6 
I Rotenone 3 4 6 6 6 
II Carboxin 5 6 6 6 6 
 TTFA 6 6 6 6 6 
 3-NPA 6 6 6 6 6 
AOX BHAM 6 6 6 6 6 
 SHAM 6 6 6 6 6 
III AntA 4 6 6 6 6 
 Kre-Me 3 5 6 6 6 
 PCS 3 4 6 6 6 
 AZS 4 6 6 6 6 
IV KCN 6 6 6 6 6 
 Na-azide 3 4 6 6 6 
a.TTFA, Thenoyltrifluoroacetone; 3-NPA, 3-Nitropropionic acid; BHAM, Benzhydroxamic acid; SHAM, 
Salicylhydroxamic acid; AntA, Antimycin A; Kre-Me, Kresoxim methyl; PCS, Pyraclostrobin; AZS, 
Azoxystrobin; KCN, Potassium cyanide; Na-azide, Sodium azide. Numbers represented highest dilution level 
(log10) where cell growth was visible. Numbers in bold show cell growth was inhibited (viz., < 6). 
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Figure 2. Differential antifungal activity of MRC inhibitors, targeting complexes I - IV or 
AOX, in yeast pathogens. (a) Representative yeast dilution bioassay showing 
Cryptococcus strains, non-fermentors, are relatively more sensitive to MRC inhibitors 
(rotenone, carboxin, PCS, Na-azide) than Candida strains, fermentors. 100 to 10−5, yeast-cell 
dilution level; Numbers on the right side of each row (0 to 6), log10 score of cell numbers 
visible (survived) (See Experimental section and Table 3). (b) Yeast dilution bioassay 
showing PCS is the most potent MRC inhibitor tested, followed by rotenone (Cell dilution 
level showing visible growth equates to antifungal potency [higher dilution score with 
visible growth = lower potency]; PCS, average log10 score = 3.4 ± 0.9 vs. rotenone, average 
log10 score = 4.6 ± 1.2. Average log10 score was determined in nine Cryptococcus strains). 
As observed in panel (a), Candida strains did not exhibit growth inhibition to any of the 
MRC inhibitors tested. 
 
2.2. Antifungal Chemosensitization Tests in Yeast Pathogens 
2.2.1. Selection of OG and 2,3-DHBA as the Most Potent Chemosensitizers 
Next, we identified the most potent antifungal chemosensitizer(s), among four phenolic compounds 
listed in Table 1, which inhibit functions of fungal mitochondria. Based on agar plate-based yeast 
dilution bioassay (See Experimental section), we determined minimum inhibitory concentrations 
(MICs) of OG, PG, 2,3-DHBA and AcSA. As shown in Table 4, OG and 2,3-DHBA possessed the 
highest antifungal activity (i.e., low MIC values) compared to PG or AcSA. Of note, Candida strains 
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were generally more tolerant to the phenolic compounds tested compared to Cryptococcus strains. 
Based on these results, OG and 2,3-DHBA were selected as the chemosensitizers to test with PCS. 
Table 4. MIC (mM) of four phenolic compounds tested in this study: agar plate-based 
yeast dilution bioassays a. 
a MIC: Minimum inhibitory concentration, where no yeast growth was observed in any dilution spots on the agar plate. 
2.2.2. Chemosensitization in Cryptococcus: 2,3-DHBA + PCS 
Antifungal chemosensitization was tested based on the EUCAST checkerboard microdilution 
bioassay protocol [32] (concentrations of compound examined were listed in Experimental section). 
For MICs, “synergistic” Fractional Inhibitory Concentration Indices (FICIs; see Experimental section 
for calculations) (i.e., FICI ≤ 0.5) were found between 2,3-DHBA and PCS for most Cryptococcus 
strains (Table 5). Despite the absence of calculated synergism, as determined by “indifferent” 
interactions [34] (Table 5), there was increased antifungal activity of 2,3-DHBA and PCS (i.e., 
chemosensitization; FICI = 0.8) in C. neoformans 4567, which was reflected in lowered MICs of  
2,3-DHBA or PCS when combined. However, for Minimum Fungicidal Concentrations (MFCs), 
“synergistic” Fractional Fungicidal Concentration Indices (FFCIs) (at the level of ≥ 99.9% fungal 
death) between 2,3-DHBA and PCS occurred only in C. neoformans strains 4565 and CN24 (Table 5). 
Therefore, results indicated that the 2,3-DHBA-mediated chemosensitization with PCS is fungistatic, 
not fungicidal (i.e., Mean MFCcombined for 2,3-DHBA or PCS/ Mean MICcombined for 2,3-DHBA or PCS 
was > 4 [See [35] for reference]), in most Cryptococcus strains tested. 
Table 5. Antifungal chemosensitization of 2,3-DHBA (mM) to PCS (μg/mL) tested 











































Strains OG PG 2,3-DHBA AcSA 
C. neoformans 90112 0.1 > 10 0.2 7 
C. gatti 4560 0.1 > 10 0.3 7 
C. albicans 90028 0.3 > 10 1.0 > 10 
C. glabrata 90030 0.2 > 10 2.0 > 10 
C. krusei 6258 0.3 > 10 2.0 > 10 
Average 0.2 ± 0.1 > 10 1.1 ± 0.9 > 8.8 ± 1.6 
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p < 0.005 






























































































p < 0.05 
p < 0.005 
- 
- 
a Synergistic FICIs and FFCIs are indicated in bold; b PCS was tested up to 16 μg/mL. For calculation 
purposes, 32 μg/mL (doubling of 16 μg/mL) was used; c Student’s t-test for paired data, mean MIC or MFC 
of each compound (combined, i.e., chemosensitization) vs. mean MIC or MFC of each compound (alone, i.e., 
no chemosensitization), was determined in nine strains (Calculation was based on [36]). 
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2.2.3. Chemosensitization in Candida: 2,3-DHBA + PCS 
The effect of “2,3-DHBA + PCS” chemosensitization was also examined in the Candida where “no 
synergistic” FICIs were found. However, there was increased antifungal activity with 2,3-DHBA + 
PCS (i.e., chemosensitization) in five strains (i.e., all three C. krusei strains, C. albicans CAN242 and 
C. glabrata CAN252), as reflected in lower MICs of each compound when co-applied (Table 6) than 
when applied alone. However, FICIs for the remaining four Candida strains and FFCIs for all Candida 
were 2.0 (i.e., no compound interactions occurred at all), indicating these fermenting yeast strains were 
relatively tolerant to any chemosensitization exerted by “2,3-DHBA + PCS.” 
Table 6. Antifungal chemosensitization of 2,3-DHBA (mM) to PCS (μg/mL) tested 



















































































p < 0.01 
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a PCS was tested up to 16 μg/mL. For calculation purposes, 32 μg/mL (doubling of 16 μg/mL) was used.  
b Student’s t-test for paired data, mean MIC or MFC of each compound (combined, i.e., chemosensitization) 
vs. mean MIC or MFC of each compound (alone, i.e., no chemosensitization), was determined in nine strains 
(Calculation was based on [36]). c N/D, not determined (all > 16 μg/mL). 
2.2.4. Chemosensitization in Cryptococcus: OG + PCS 
Next, chemosensitization efficacy of “OG + PCS” in Cryptococcus was evaluated. For MICs, 
synergistic FICIs were achieved for most of the Cryptococcus strains (Table 7). Similar to the results 
for “2,3-DHBA + PCS”, the only exception for achieving synergism was C. neoformans 4567, which 
was determined to be an “indifferent” interaction. However, increased antifungal activity of OG and 
PCS (i.e., chemosensitization; FICI = 0.6) could be achieved in C. neoformans 4567, resulting in 
lowered MICs of OG or PCS when co-applied. 
For MFCs, synergistic FFCIs (at the level of ≥ 99.9% fungal death) between OG and PCS occurred 
in all Cryptococcus strains (Table 7), reflecting the most potent antifungal activity of OG, as 
determined in Table 4. Most notable is that the concentration of OG needed to achieve synergism with 
PCS was much lower than that for 2,3-DHBA, i.e., chemosensitizing potency (higher to lower, as 
indicated by lower concentrations required) = OG (0.01–0.02 mM) > 2,3-DHBA (0.2–1.6 mM; See 
also Table 5). 
Table 7. Antifungal chemosensitization of OG (mM) to PCS (μg/mL) tested against 
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p < 0.005 
































































































p < 0.005 
p < 0.005 
- 
- 
a Synergistic FICIs and FFCIs are indicated in bold; b PCS was tested up to 16 μg/mL. For calculation 
purposes, 32 μg/mL (doubling of 16 μg/mL) was used; c Student’s t-test for paired data, mean MIC or MFC 
of each compound (combined, i.e., chemosensitization) vs. mean MIC or MFC of each compound (alone, i.e., 
no chemosensitization), was determined in nine strains (Calculation was based on [36]). 
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2.2.5. Chemosensitization in Candida: OG + PCS 
The chemosensitization effect of “OG + PCS” was further examined in the Candida strains. For 
MICs, “synergistic” FICIs were found in four strains, i.e., all three C. krusei strains and C. glabrata 
CAN252 (Table 8). This synergism was not detected with “2,3-DHBA + PCS”, further reflecting the 
higher antifungal activity of OG than 2,3-DHBA (See also Table 6). Despite the “indifferent” 
interaction, increased antifungal activity of OG and PCS (i.e., chemosensitization; FICI = 0.6) occurred in 
C. albicans CAN242, as determined in lowered MICs of OG or PCS when combined (Table 8). 
Of note, the trends of compound interactions of OG + PCS for MICs in Table 8 were congruent with 
“2,3-DHBA + PCS” chemosensitization (Table 6). For both “2,3-DHBA + PCS” and “OG + PCS”, 
incremental increase of growth inhibition occurred in five common strains, i.e., all three C. krusei 
strains, C. albicans CAN242 and C. glabrata CAN252 (Tables 6 and 8). This indicated that strain 
specificity to chemosensitization also exists. This is reflected in the level of differential vulnerability of 
each strain to chemosensitization (See also FICIs of C. neoformans 4567 in Tables 5 and 7, showing 
lower sensitivity of this strain to both OG- and 2,3-DHBA-mediated chemosensitization compared to 
other Cryptococcus strains). 
For MFCs, synergistic FFCIs (at the level of ≥99.9% fungal death) between OG and PCS were 
achieved in C. krusei CAN82 and C. glabrata CAN252. While the FFCI of C. krusei 6258 was scored as 
“indifferent”, there was increased antifungal activity of OG and PCS (i.e., chemosensitization; FFCI = 0.6) 
with this strain. FFCIs for the remaining strains were “indifferent”, and as observed in “2,3-DHBA + PCS” 
assays, Candida strains were more tolerant to “OG + PCS” chemosensitization compared to 
Cryptococcus strains. 
Table 8. Antifungal chemosensitization of OG (mM) to PCS (μg/mL) tested against 
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p < 0.05 





















































































p < 0.5 
p < 0.1 
- 
- 
a Synergistic FICIs and FFCI are indicated in bold. b PCS was tested up to 16 μg/mL. For calculation 
purposes, 32 μg/mL (doubling of 16 μg/mL) was used. c Student’s t-test for paired data, mean MIC or MFC 
of each compound (combined, i.e., chemosensitization) vs. mean MIC or MFC of each compound (alone, i.e., 
no chemosensitization), was determined in nine strains (Calculation was based on [36]). 
The results of all chemosensitization tests (i.e., PCS + 2,3-DHBA or OG in both Cryptococcus and 
Candida strains) are summarized in Table 9. Exemplary MFC test results, based on chemosensitization 
(PCS + OG or 2,3-DHBA) performed in Cryptococcus or Candida strains, are provided in Figure 3. 
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Table 9. SUMMARY: Antifungal chemosensitization of OG or 2,3-DHBA (mM) to PCS 
(μg/mL) tested against Cryptococcus or Candida strains determined by EUCAST-based 
microdilution bioassays. Data shown are mean values derived from Table 5 to 8. a 
a Synergistic FICIs and FFCI are indicated in bold. 
Figure 3. (a) Diagram describing effects of OG- or 2,3-DHBA-mediated 
chemosensitization to PCS in “most” Cryptococcus strains (non-fermentors) or in “selected 
(e.g., five sensitive strains described in Tables 6 and 8)” Candida strains (fermentors).  
(b) Representative MFC test results performed in C. neoformans 208821 and C. albicans 
90028 after chemosensitization (PCS + OG). Results showed that C. neoformans 208821 
(non-fermentor) was more sensitive (i.e., “no growth” with PCS4.0 μg/mL + OG0.01 mM) to the 
chemosensitization than C. albicans 90028 (fermentor) (i.e., “growth” with PCS4.0 μg/mL + 
OG0.01 mM). (c) Representative MFC test results performed in C. neoformans 90112 and 
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2.2.6. Differential Responses of S. cerevisiae Antioxidant Mutants to OG or 2,3-DHBA 
Identification of fungal target(s) of OG or 2,3-DHBA within the antioxidant system was attempted 
using gene deletion mutants of the model yeast, S. cerevisiae. Agar plate-based yeast dilution 
bioassays on SG with OG or 2,3-DHBA (See Experimental section for test concentrations), in 
duplicate, included the wild type (WT) and five antioxidant mutant strains, as follows: (1) yap1Δ 
(Yap1p is the transcription factor regulating expression of four downstream genes within the oxidative 
stress response pathway, i.e., GLR1 [glutathione reductase], YCF1 [a glutathione S-conjugate pump], 
GSH1 [γ-glutamylcysteine synthetase, which catalyzes the first step in glutathione biosynthesis] and 
TRX2 [thioredoxin] [37,38]), (2) sod2Δ (mitochondrial superoxide dismutase, Mn-SOD), (3) trr1Δ 
(cytoplasmic thioredoxin reductase), (4) trr2Δ (mitochondrial thioredoxin reductase), and (5) tsa1Δ 
(thioredoxin peroxidase) (See Saccharomyces Genome Database [30]). 
Of the five deletion mutants, yap1Δ was hypersensitive to OG (log10 = 4), while sod2Δ was 
hypersensitive to 2,3-DHBA (log10 = 5) (Figure 4) (see also [15]). These results indicate OG or 2,3-DHBA 
affect different cellular components in fungi, where Mn-SOD plays a relatively greater role in fungal 
tolerance to 2,3-DHBA, while glutathione homeostasis, etc., protects cells from OG-induced toxicity, 
compared to the other genes represented. Further studies, such as microarray-based chemogenomic 
analysis, inclusion of more gene deletion mutants, etc., are warranted to determine the precise 
mechanism of action of OG or 2,3-DHBA during chemosensitization. 
Figure 4. Agar plate-based yeast dilution bioassay identifying sensitive mutants of S. 
cerevisiae to phenolic chemosensitizers (100 to 10−5: yeast dilution rates). Results showed 
the sensitive responses of yap1Δ to OG and sod2Δ to 2,3-DHBA, respectively. 
 
3. Experimental 
3.1. Yeast Strains 
Yeast strains (Cryptococcus- C. neoformans, C. gatti; Candida- C. albicans, C. glabrata, C. krusei; 
Saccharomyces cerevisiae; See Table 2) were cultured on synthetic glucose (SG; yeast nitrogen base 
without amino acids 0.67%, glucose 2% with appropriate supplements: uracil 0.02 mg/mL, amino 
acids 0.03 mg/mL) or Yeast Peptone Dextrose (YPD; Bacto yeast extract 1%, Bacto peptone 2%, 
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glucose 2%) medium at 35 °C for yeast pathogens (Candida, Cryptococcus) or 30 °C for S. cerevisiae, 
respectively. 
3.2. Chemicals 
The chemosensitizing agents (octyl gallate [OG], propyl gallate [PG], 2,3-dihydroxybenzaldehyde 
[2,3-DHBA], acetylsalicylic acid [AcSA], proguanil) and inhibitors of mitochondrial respiratory chain 
(MRC) (rotenone, carboxin, thenoyltrifluoroacetone [TTFA], 3-nitropropionic acid [3-NPA], 
benzhydroxamic acid [BHAM], salicylhydroxamic acid [SHAM], antimycin A [AntA], kresoxim 
methyl [Kre-Me], pyraclostrobin [PCS], azoxystrobin [AZS], potassium cyanide [KCN], sodium azide 
[Na-azide], atovaquone [ATQ]) were procured from Sigma Co. (St. Louis, MO, USA). Each 
compound was dissolved in dimethyl sulfoxide (DMSO; absolute DMSO amount: < 1% in media) 
before incorporation into culture media. In all tests, control plates (i.e., “No treatment”) contained 
DMSO at levels equivalent to that of cohorts receiving antifungal agents, within the same set  
of experiments. 
3.3. Antifungal Bioassay: Microtiter Plate (Microdilution) Bioassay 
Chemosensitizing activity of OG (0.005, 0.01, 0.02, 0.04, 0.08, 0.16, 0.32, 0.64 mM) or 2,3-DHBA 
(0.05, 0.1, 0.2, 0.4, 0.8, 1.6, 3.2, 6.4 mM) to PCS (0.25, 0.5, 1, 2, 4, 8, 16 µg/mL) was determined by 
using checkerboard bioassays in microtiter plates (with RPMI 1640 medium; Sigma Co.). To 
determine changes in MICs of antifungal agents (i.e., PCS and chemosensitizers) in microtiter wells, 
checkerboard bioassays (0.5 × 105 to 2.5 × 105 CFU/mL) were performed using broth microdilution 
protocols according to methods outlined by the European Committee on Antimicrobial Susceptibility 
Testing (EUCAST) [32]. Minimum inhibitory concentration (MIC) for chemosensitization was defined 
as the lowest concentration of agent(s) where no fungal growth was visible at 24 and 48 h. All 
bioassays were performed in triplicate. Statistical analysis was based on [36]. Microtiter plate 
(microdilution) bioassay was also performed to determine chemosensitizing activity of proguanil (0.25, 
0.5, 1, 2, 4, 8, 16 μg/mL) to ATQ (0.25, 0.5, 1, 2, 4, 8, 16 μg/mL). Minimum fungicidal concentration 
(MFC), which is the lowest concentration of agents exhibiting ≥ 99.9% fungal death, were determined 
(after completion of MIC assays) wherein entire volumes of microtiter wells (200 µL) were spread 
onto individual YPD plates, and cultured for another 48 and 72 h. Compound interactions, Fractional 
Inhibitory Concentration Indices (FICI) and Fractional Fungicidal Concentration Indices (FFCI) were 
calculated, as follows: FICI or FFCI = (MIC or MFC of compound A in combination with compound 
B/MIC or MFC of compound A, alone) + (MIC or MFC of compound B in combination with 
compound A/MIC or MFC of compound B, alone). Interactions were defined as: “synergistic” (FICI or 
FFCI ≤ 0.5) or “indifferent” (FICI or FFCI > 0.5–4) [34]. 
3.4. Antifungal Bioassay: Agar Plate (Yeast Dilution) Bioassay 
Petri plate-based yeast dilution bioassays were performed on the wild type and antioxidant mutants 
(trr1Δ, trr2Δ, tsa1Δ, sod2Δ, yap1Δ) to assess the effects of OG (0.005, 0.01, 0.015, 0.02, 0.025, 0.03, 
0.035, 0.04, 0.045, 0.05, 0.1 mM) and 2,3-DHBA (0.005, 0.01, 0.015, 0.02, 0.025, 0.03, 0.035, 0.04, 
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0.045, 0.05, 0.1, 0.2, 0.3 mM) on the antioxidant system. Similar yeast dilution bioassays were also 
performed on strains of Cryptococcus or Candida to assess antifungal capacity/effects of OG (0.1, 0.2, 
0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0 mM), 2,3-DHBA (0.0125, 0.025, 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 0.4, 
0.5, 1.0, 2.0, 3.0 mM), PG (1, 2, 3, 4, 5, 6, 7, 8, 9, 10 mM), AcSA (1, 2, 3, 4, 5, 6, 7, 8, 9, 10 mM) or 
MRC inhibitors (100 μM). 
These assays were performed in duplicate on SG agar following previously described protocols [15] 
as follows: 1 × 106 cells of the wild type or gene deletion mutants of S. cerevisiae, Cryptococcus or 
Candida, cultured on YPD, were serially diluted 10-fold in SG liquid medium (supplemented with 
amino acids and uracil, if required) five times, which yields cell dilution cohorts of 106, 105, 104, 103, 
100 and 10 cells. Cells from each dilution of respective yeast strains were spotted adjacently on SG 
agar medium incorporated with antifungal compounds to be tested and incubated at 30 °C or 35 °C for 
S. cerevisiae or Cryptococcus/Candida, respectively. Results were monitored based on a designated 
log10 score of the highest dilution where a colony became visible after 3–5 days of incubation, as follows: 
Score ‘0’—no colonies were visible from any of the dilutions, Score ‘6’—colonies were visible from 
all dilutions, Score ‘1’—only a colony from the undiluted cells (i.e., 106 cells), ‘2’ only colonies from 
the undiluted and 105 cells were visible, etc. Therefore, each unit of numerical difference (e.g., 102 vs. 103) 
was equivalent to a 10-fold difference in the sensitivity of the yeast strain to the treatment. 
3.5. Statistical Analysis 
Statistical analyses, e.g., chemosensitization vs. no chemosensitization, were performed based on [36]. 
4. Conclusions 
In summary, OG- or 2,3-DHBA-based chemosensitization can enhance antifungal activity of PCS 
in Cryptococcus and Candida. Our results showed that: (1) All Cryptococcus strains (non-fermentors) 
were sensitive to PCS + OG or 2,3-DHBA; (2) Only selected Candida strains (three C. krusei strains, 
C. albicans CAN242, C. glabrata CAN252) (fermentors) were sensitive to PCS + OG or 2,3-DHBA; 
(3) OG was a more potent chemosensitizer than 2,3-DHBA to PCS, where the concentration of OG 
required to achieve “synergism” was much lower (≥20 times lower) than 2,3-DHBA in either 
Cryptococcus or Candida strains; (4) “chemosensitization - strain specificity” exists, which reflects 
differential vulnerability of tested strains to the chemosensitization; (5) OG or 2,3-DHBA disrupt 
different cellular components in fungi, where Mn-SOD plays a role in fungal tolerance to 2,3-DHBA, 
while glutathione homeostasis, etc., are responsible for protecting cells from OG-triggered toxicity. 
The MRC is recently recognized as a new target for development of clinical antimycotics [24,39]. 
For example, co-application of AntA (MRC-inhibitory) and BHAM (AOX-inhibitory) significantly 
increased the activity of triazole drugs, potentiating the antifungal activity of the drugs as fungicidal in 
R. oryzae (causative agent of mucormycosis) [24]. Also, inhibition of MRC of C. parapsilosis (causing 
neonatal and device-related infections; See [39] and references therein) enhances susceptibility of this 
fungal pathogen to caspofungin, a cell wall-targeting drug [39]. Thus, use of a chemosensitizer, as 
described in this study, would lower the effective dose of an MRC-inhibitory drug, thus lowering potential 
side effects of these drugs and others that might be co-applied (i.e., azoles, caspofungin, etc.). This 
lower dosage would render treatment less expensive and safer, thus making their use more acceptable. 
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In conclusion, OG and/or 2,3-DHBA show potential to serve as antifungal chemosensitizers that in 
combination with PCS greatly enhance antifungal activity. This capacity was shown to be most 
effective against Cryptococcus, etiologic agents for the leading cause of death among those suffering 
from immunocompromised disorders. Chemosensitizers, especially those proven to be safe 
compounds, such as natural phenolic agents or their structural derivatives, could serve as potential 
“leads” against yeast pathogens for more effective treatment of mycoses using MRC inhibitory drugs. 
Determination of precise mechanisms of action of chemosensitization as well as identification of 
effective MRC-inhibitory drugs which selectively interfere with fungal mitochondrial function, and not 
human (mammalian), must be ensured through future study. 
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